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1. Introduction
  Toxoplasma gondii(T. gondii), an obligate intracellular 
protozoan, is one of the most prevalent protozoa in 
man and livestock[1] and widely distributed around the 
world[2]. The prevalence of serologic evidence of T. gondii 
infection varies depending on geographic areas and 
population group. T. gondii is horizontally transmitted to 
humans by accidental ingestion of oocysts in water, food 
or soil contaminated with cat’s feces, or by eating raw or 
undercooked meat containing cysts[3]. Most infections in 
immunocompetent humans are asymptomatic and in up 
to 10% of infected individuals cervical lymphadenopathy 
or ocular disease occur[4]. T. gondii can also cause severe 
encephalitis via acute infection or reactivation of latent 
infection among immune-suppressed persons, including 
those with acquired immunodeficiency syndrome, those 
with immunosuppressive cancer, and transplant recipients 
on immunosuppressive drugs. Toxoplasmosis is the most 
frequent severe neurologic infection among persons with 
acquired immunodeficiency syndrome[4,5].
  Toxoplasmic encephalitis usually occurs in HIV-infected 
patients with CD4 T-cell counts<100/毺L[6]. In Iran, up to 
50% prevalence of Toxoplasma infection has been estimated 
in different risk groups[7]. Although latent Toxoplasma 
infection is an important problem among HIV patients, it has 
not been performed any study in north of Iran. Therefore, 
this study conducted to determine the seroprevalence of 
anti-T. gondii IgG and IgM antibodies in HIV/AIDS patients 
and HIV-uninfected subjects in this area. 
Objective: To determine the seroprevalence of anti-Toxoplasma gondii (T. gondii)  IgG and IgM 
antibodies in HIV/AIDS patients and uninfected subjects. Methods: This cross sectional survey 
was carried out on 78 healthy and 62 HIV+/AIDS individuals in northern Iran between September 
2007 and October 2008. Five mL of blood samples were collected from each person in case and 
control groups. Determination of CD4+ counts was performed by flow cytometry. The serum 
separated from blood samples was evaluated by conventional ELISA technique to determine 
the presence of antibodies to T. gondii. Results: Forty eight out of 62 (77.4%) HIV/AIDS serum 
samples were found positive for anti-T. gondii IgG antibody, compared with 59 among 78 (75.6%) 
HIV negative samples from the same area (P>0.05). Six out of 62 (9.7%) HIV+/AIDS patients 
showed anti-T. gondii IgM antibody in their serum samples, compared with 7 among 78 (9%) HIV 
negative samples(P>0.05). The mean of CD4+ counts in HIV+/AIDS was (430.8依182.3) cells/毺L and 
in control group was (871.0依243.3)% cells/毺L (P<0.01). CD4
+ estimation in 5 (11.1%) of HIV+/AIDS 
patients was <200 cells/毺L (P<0.000 1). Conclusions: Seroprevalence of latent toxoplasmosis 
in HIV patients is high, therefore the prevention of toxoplasmic encephalitis, administration of 
primary prophylaxis with co-trimoxazole to all HIV+/AIDS patients are necessary.
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2. Materials and methods
  This cross sectional survey was carried out on 78 healthy 
and 62 HIV+/AIDS individuals in northern Iran between 
September 2007 and October 2008. This study was previously 
assessed and approved by the Ethics Committee at the 
Mazandaran University of Medical Sciences.
2.1.Collection and examination of blood samples
  Five mL of Blood samples were collected from each person 
in case and control groups. The subjects gave an informed 
consent. Determination of CD4+ counts was performed by 
flow cytometry including whole blood samples collected 
in EDTA  from 78 normal and 62 HIV+/AIDS individuals. 
Immunophenotyping of the lymphocyte subsets was done 
by using three color flow cytometric methods (partech, 
Germany). The blood samples were stained by using FITC 
conjugated mouse anti-human CD4 (clone MT 310) and 
mouse anti-human CD3 (clone UCHTI) conjugated with 
RPECYS monoclonal antibodies. All reagents were purchased 
from Dakocytomation (Dakocytomation, Denmark). The 
serum separated from blood samples was stored at -20 曟 
until use. The presence of antibodies to T. gondii was 
determined by conventional ELISA technique, according 
to the manufacturer,s instructions (EUROIMMUN, D-23560 
Lubeck. Seekamp 31. Germany). The optical density of 
IgG antibody titers were read at 490 nm using automatic 
ELISA reader (SPECTRA, Molecular Devices, USA). Sera with 
≥20 IU/mL and ≥100 IU/mL were considered positive for 
anti-T. gondii immunoglobulin IgG and IgM antibodies, 
respectively. 
2.2. Statistical analysis
  SPSS software 16 was used for statistical analysis. Possible 
association were identified using the Chi-square and 
Fisher’s exact statistical tests at a significant level of 5%.
 
3. Results
  A total of 140 individuals were enrolled in the study. Sixty 
two HIV+/AIDS patients (case group) and 78 without clinical 
signs (control group) were examined for anti-T. gondii IgG 
and IgM antibodies.
  The age range of HIV+/AIDS infected participants was 17 to 
58 years with a median of (32.6依7.4) years and the mean age 
of HIV negative individuals was (32.7依9.5) years  (range 12-
62 years).
  Forty eight out of 62 (77.4%) HIV positive/AIDS serum 
samples were found positive for anti-T. gondii IgG antibody, 
compared with 59 among 78 (75.6%) HIV negative samples 
from the same area (P>0.05). Except age groups ≤ 20 (n=1) 
and ≥51 years (n=1), prevalence of IgG antibody was higher 
in age group of 41-50 years old. There was no statistical 
significant difference among age groups (Table 1).
  Six out of 62 (9.7%) HIV+/AIDS patients showed anti-T. 
gondii IgM antibody in their serum samples, compared 
with 7 among 78 (0.9%) HIV negative samples (P>0.05). 
Frequency of IgM antibody concerning age has been shown 
in Table 1.
  CD4+ T-cell count was done in all HIV-positive and control 
people. The mean of CD4+ counts in HIV+/AIDS was (430.8依
182.3) cells/毺L and in control group was (871.0依243.3) cells/ 
毺L (P<0.01).
  Ninety two percent of people in control group and 25.5% of 
HIV+/AIDS patients had a CD4+ T lymphocyte count of ≥500 
cells/毺L (P<0.000 1). CD4
+ estimation in 5 (11.1%) of HIV+/
AIDS patients was <200 cells/毺L (P<0.000 1) (Table 2).
Table 1 
Frequency of anti-T. gondii IgM and IgG antibodies in age groups [n(%)].
Age groups (Years)
IgM+ IgG+
Case Control Case Control
≤20     1 (100.0)   1 (10.0)    1 (100.0)  8 (80.0)
21-30 1 (5.3)   2 (10.6) 13 (68.4) 16 (84.2)
31-40 3 (9.7) 3 (9.7) 24 (77.4) 20 (64.5)
41-50   1 (10.0) 1 (6.3)   9 (90.0)  14 ( 87.5)
≥51 0 (0.0) 0 (0.0)     1 (100.0)    1 (50.0)
Total 6 (9.7) 7 (8.9)  48 (77.4) 59 (75.6)
Table 2
Frequency of CD4+ Tcells counts in HIV+/AIDS patients (case) and healthy people (control) by IgG and IgM positive against T. gondii [n(%)].
Antibodies
<200  200-499 ≥500 Total
HIV+ HIV-       HIV+       HIV- HIV+ HIV- HIV+ HIV- 
IgG+   5 (11.1) 0 (0.0)  29 (64.4) 4 (8.0) 11 (24.4) 46 (92.0) 45 (100.0) 50 (100.0)
IgM+ 0 (0.0) 0 (0.0)    4 (66.7) 0 (0.0)   2 (33.3)   4 (100.0)   6 (100.0)  4 (100.0)
Some samples of case and control groups were not evaluated for CD4 counts.
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4. Discussion
  In this study, the seroprevalence rates of anti-T. gondii 
IgG antibody due to reactivation of a latent infection 
among HIV+/AIDS patients and healthy people were 77.4% 
and 75.6%, respectively. Individuals in both groups had 
similar exposure to T. gondii infection, as reported by other 
researches[8-10]. The high prevalence of anti-T. gondii 
IgG antibody in these individuals was like the results of 
previous surveys carried out on the pregnant women of 
Mazandaran Province, Iran[11]. In Iran there are few reports 
about prevalence of anti-T. gondii antibodies in HIV+/
AIDS people. Mardani et al[12] in Ghom Province reported 
the same prevalence (61.33%), but Davarpanah et al[13] in 
Shiraz, southern Iran and Afrasiabian et al[14] in Kurdistan 
Province, north west of Iran reported low prevalence rates 
(18.2% and 46.9%, respectively). The high seroprevalence 
of latent Toxoplasma infection among individuals of this 
area is due to consumption of raw or insufficiently cooked 
meat, proper climate (high humidity) for survival of the 
oocyst of T. gondii and abundance of cats that contaminate 
the environment. In contrast, the lower prevalence might be 
related to climatic condition in Kurdistan (cold weather) and 
Shiraz (warm and dry weather). 
  There is wide geographic variation in the prevalence of 
latent T. gondii infection. Studies from different continents 
such as Latin America, Europe, Asia, and Africa have 
reported a range of prevalence estimates of 30%-75%, 
whereas prevalence estimates from USA studies have had 
a range of 3%-42%[9]. However, this seroprevalence was 
much higher than some countries e.g. 15% in Washington, 
D.C., USA[9], 44.8%-51.2% in Malaysia[6,15], 5.4% in Japan[16], 
and 50% in Ethiopia[10]. The differences could be due to the 
geographical distribution, feeding habits of eating raw or 
badly cooked meat, diagnostic techniques, or sample size, 
and foods contaminated with cat feces containing T. gondii 
oocysts. 
  Since presence of IgG antibodies to T. gondii represents 
chronic infection and is an index for development of 
toxoplasmosis, therefore serological tests help us to identify 
those HIV+/AIDS patients who have IgG antibodies to T. 
gondii and are at risk for development of Toxoplasma 
encephalitis (TE). TE represents an important opportunistic 
infection in HIV+/AIDS patients[16]. Almost all AIDS patients 
with TE have detectable anti-T. gondii IgG antibodies in 
their serum. TE in a negative T. gondii IgG antibody test is 
less likely. Therefore situation of IgG antibody should be 
determined in all HIV+/AIDS patients. Seropositive patients 
need to start oral treatment for toxoplasmosis prophylaxis 
and without it almost one-third of these patients develop 
toxoplasmosis[17].
  In the USA, it is estimated that 20% to 47% of all 
the patients with HIV develop encephalitis caused by 
toxoplasmosis and 25% to 50% in Europe and Africa[17,18]. 
The estimated disease is related to the incidence of 
toxoplasmosis in each area, which is higher in France[19] 
and Brazil[20], to the absence of chemoprophylaxis[21] and to 
low CD4+ counts[22], specific strain virulence[23] or genetic 
background[24]. TE is reported to occur at <200 cells+high 
IgG tites ≥150 i.u./mL in France[25], <100 cells/毺L in 
USA[26-29] and 35 times more common in those with CD4+<50 
cells/毺L in Edinburg[30]. In this study the mean CD4
+ count 
in HIV+/AIDS patients was (430.8依182.3) cells/毺L blood and 
5/45 patients with anti-T. gondii IgG antibody showed CD4 
count<200/毺L; therefore the risk observed in our study 
was 11.1%. These patients would have a higher chance to 
develop toxoplasmic encephalitis than others who had CD4 
count>200 cell/毺L. In clinical practice, CD4 cell count is 
considered to be a prognostic or risk factor to monitor the 
progression of HIV infection. 
  In this survey, 9.7% HIV+/AIDS patients showed anti-T. 
gondii IgM antibody. Afrasiabian et al[14] in Kurdistan also 
reported the same prevalence (10.9%). But Mardani et al[12] 
in Ghom Province showed that no person had anti-T. gondii 
IgM antibody. Ramirez et al[31] in their study found only one 
case with IgM antibody (1.0%). Of course IgM antibody test 
play no role in the diagnosis of toxoplasmosis in patients 
with HIV, because the disease is usually due to reactivation 
of a dormant cyst.
  In conclusion, in this survey the seroprevalence of chronic 
(latent) toxoplasmosis was high and similar among HIV+/
AIDS patients and healthy people. Therefore, we propose 
that all HIV+/AIDS patients have to be tested for T. gondii 
antibody and administration of primary prophylaxis with co-
trimoxazole to all HIV+/AIDS patients with a CD4 cell count of 
less than 200 cells/毺L is necessary.
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